Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
The New England Journal of Medicine|October 23, 2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerPeter Schmid, Sylvia Adams, Hope S Rugo, et al.
Journal of Translational Medicine|June 3, 2021
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Breast Cancer Research and Treatment|October 25, 2017
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studyLuc Y Dirix, Istvan Takacs, Guy Jerusalem, et al.
Journal of Translational Medicine|January 7, 2021
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy)Paolo A Ascierto, Lisa H Butterfield, Katie Campbell, et al.
Journal for Immunotherapy of Cancer|June 9, 2023
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancerMary L Disis, Sarah F Adams, Jyoti Bajpai, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Pageof 12